Takashi Yao

Prof. Dr. Takashi Yao

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2022 in Digestive Endoscopy
Verified
Journal Article
Open access
PDF file
TUToshio Uraoka
Toshio Uraoka
KTKOHEI TAKIZAWA
KOHEI TAKIZAWA
STShinji Tanaka
Shinji Tanaka
HKHiroshi Kashida
Hiroshi Kashida
YSYutaka Saito
Yutaka Saito
HIHaruhiro Inoue
Haruhiro Inoue
The Japan Gastroenterological Endoscopy Society published the second edition of the “Guidelines for Colorectal Endoscopic Submucosal Dissection/Endoscopic Mucosal Resection” in 2019 to clarify the indications for colorectal endoscopic mucosal resection (EMR) and endoscopic submucosal dissection and to ensure appropriate preoperative diagnoses as well as effective and safe endoscopic treatment in front‐line clinical settings. Endoscopic resection with electrocautery, including polypectomy and EMR, is indicated for colorectal polyps. Recently, the number of facilities introducing and implementing cold polypectomy without electrocautery has increased. Herein, we establish supplementary guidelines for cold polypectomy. Considering that the level of evidence for each statement is limited, these supplementary guidelines must be verified in clinical practice.

29 March 2022 in Digestive Endoscopy
Verified
Journal Article
Closed access
TMTakashi Murakami
Takashi Murakami
TKTaro Kurosawa
Taro Kurosawa
HFHirofumi Fukushima
Hirofumi Fukushima
TSTomoyoshi Shibuya
Tomoyoshi Shibuya
TYTakashi Yao
Takashi Yao
ANAkihito Nagahara
Akihito Nagahara

1 November 2012 in Human Pathology
Verified
Journal Article
Closed access
AIAbdukadir Imamhasan
Abdukadir Imamhasan
HMHiroyuki Mitomi
Hiroyuki Mitomi
STSaito Tsuyoshi
Saito Tsuyoshi
THTakuo Hayashi
Takuo Hayashi
MTMichiko Takahashi
Michiko Takahashi
TYTakashi Yao
Takashi Yao

29 October 2021 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
ASAsumi Sakaguchi
Asumi Sakaguchi
YHYoshiya Horimoto
Yoshiya Horimoto
HOHiroko Onagi
Hiroko Onagi
DIDaiki Ikarashi
Daiki Ikarashi
TNTakayuki Nakayama
Takayuki Nakayama
SKShigehisa Kitano
Shigehisa Kitano
Background: Tumour-infiltrating lymphocyte (TIL)-high breast tumours have a high rate of pathological complete response (pCR) with neoadjuvant chemotherapy. In our routine pathological diagnoses of biopsy specimens from pCR cases, we have observed a high infiltration of plasma cells (PCs). A positive correlation of PCs with favourable patient outcome has recently been reported, but little is known about how PCs contribute to local tumour immunity. Methods: We retrospectively examined biopsy specimens from 146 patients with invasive breast cancer who received neoadjuvant chemotherapy. CD138+ PC infiltration was assessed by immunohistochemistry. Multiplexed fluorescent immunohistochemistry (mfIHC) with T and B cell markers was also conducted to elucidate the profile of immune cells. Results: Greater PC infiltration was observed in the pCR group (p = 0.028) and this trend was confirmed in another patient cohort. With mfIHC, we observed significantly more CD8+, T-bet+CD4+, and CD8+FOXP3+ T cells, total B cells and PCs in pCR cases. Such cases were also characterised by high expression of both PD-1 and PD-L1 on B cells and PCs. In patients with hormone receptor-negative tumours, high PC infiltration was correlated with significantly longer disease-free survival (p = 0.034). Conclusions: We found that higher PC infiltration in biopsy specimens before neoadjuvant chemotherapy was associated with pCR. With mfIHC, we also revealed that the local cytotoxic immune response was clearly enhanced in pCR cases, as was the infiltration of B cells including PCs. Moreover, higher PC levels were correlated with favourable outcomes in hormone receptor-negative breast cancer patients.

10 October 2022 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
HOHiroko Onagi
Hiroko Onagi
YHYoshiya Horimoto
Yoshiya Horimoto
ASAsumi Sakaguchi
Asumi Sakaguchi
DIDaiki Ikarashi
Daiki Ikarashi
NYNaotake Yanagisawa
Naotake Yanagisawa
SKShigehisa Kitano
Shigehisa Kitano
Background: Rating lymphocytes (TILs) are a prognostic marker in breast cancer and high TIL infiltration correlates with better patient outcomes. Meanwhile, parameters involving immune cells in peripheral blood have also been established as prognostic markers. High platelet-to-lymphocyte ratios (PLRs) and neutrophil-to-lymphocyte ratios (NLRs) are related to poor outcomes in breast cancer, but their mechanisms remain unknown. To date, TILs and these parameters have been examined separately.Methods: We investigated the relationship between TILs and the peripheral blood markers, PLR and NLR, in the same patients, using surgical specimens from 502 patients with invasive breast carcinoma without preoperative chemotherapy. For analysis of triple-negative breast cancer (TNBC) patient outcomes, 59 patients who received preoperative chemotherapy were also examined. For immune cell profiling, multiplexed fluorescent immunohistochemistry (mfIHC) of CD3, CD4, CD8, FOXP3 and T-bet, was conducted.Results: A positive correlation between PLR and TIL was observed in TNBC (P = 0.013). On mfIHC, tumors in patients with high PLR and NLR contained more CD3+CD4+FOXP3+T-cells (P = 0.049 and 0.019, respectively), while no trend was observed in CD8+T-cells. TNBC patients had different patterns of outcomes according to TIL and PLR, with the TIL-high/PLR-low group having the lowest rate of disease relapse and death, and the longest distant metastasis-free and overall survivals, while the TIL-low/PLR-high group had the shortest survivals.Conclusions: Our data suggest that the combination of PLR with TIL assessment may enable more accurate prediction of patient outcomes with TNBC.

20 November 2018 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
TMTakashi Murakami
Takashi Murakami
YAYoichi Akazawa
Yoichi Akazawa
NYNoboru Yatagai
Noboru Yatagai
THTakafumi Hiromoto
Takafumi Hiromoto
NSNoriko Sasahara
Noriko Sasahara
TYTakashi Yao
Takashi Yao
Colorectal sessile serrated adenoma/polyps (SSA/Ps) are considered early precursor lesions in the serrated neoplasia pathway. Recent studies have shown associations of SSA/Ps with lost MLH1 expression, a CpG island methylator phenotype, and BRAF mutations. However, the molecular biological features of SSA/Ps with early neoplastic progression have not yet been fully elucidated, owing to the rarity of cases of SSA/P with advanced histology such as cytologic dysplasia or invasive carcinoma. In this study, we aimed to elucidate the molecular biological features of SSA/Ps with dysplasia/carcinoma, representing relatively early stages of the serrated neoplasia pathway. We performed immunostaining for β-catenin, MLH1, and mucins (e.g., MUC2, MUC5AC, MUC6, and CD10); targeted next-generation sequencing; and microsatellite instability (MSI) testing in 8 SSA/P lesions comprised of 4 SSA/Ps with high-grade dysplasia and 4 SSA/Ps with submucosal carcinoma. Lost MLH1 expression was found in 5 cases. All lesions studied were positive for nuclear β-catenin expression. Regarding phenotypic mucin expression, all lesions were positive for MUC2, but negative for CD10. MUC5AC and MUC6 positivity was observed in 7 cases. Genetically, the most frequently mutated gene was BRAF (7 cases), and other mutations were detected in FBXW7 (3 cases); TP53 (2 cases), and KIT, PTEN, SMAD4, and SMARCB1 (1 case each). Furthermore, 4 of 8 lesions were MSI-high and the remaining 4 lesions were microsatellite-stable (MSS). Interestingly, all 4 MSI-high lesions displayed MLH1 loss, 3 of which harbored a FBXW7 mutation, but not a TP53 mutation. However, 2 MSS lesions harbored a TP53 mutation, although none harbored a FBXW7 mutation. SSA/Ps with dysplasia/carcinoma frequently harbored BRAF mutations. Activation of the WNT/β-catenin signaling pathway may facilitate the development of dysplasia in SSA/Ps and progression to carcinoma. Furthermore, our results suggested that these lesions might be associated with both MSI-high and MSS colorectal cancer, which might be distinguished by distinct molecular biological features such as lost MLH1 expression, FBXW7 mutations, and TP53 mutations.